Menu
  • Join
  • Login
  • Contact
 

Search abstracts


EFFICACY AND SAFETY OF 12-WEEK LEDIPASVIR/SOFOSBUVIR IN PATIENTS WITH CHRONIC HEPATITIS C

  • At: 2019 FIP Congress in AbuDhabi (United Arab Emirates)
  • Type: Poster
  • By: LIU, Min-Li (E-Da Cancer Hospital, Department of Pharmacy, China Taiwan)
  • Co-author(s): Min-Li Liu: Department of Pharmacy, E-Da Cancer Hospital, Kaohsiung, China Taiwan
    Yung-Chia Hsu: Department of Pharmacy, E-Da Cancer Hospital, Kaohsiung, China Taiwan
    Yi-Ping Hsiang: Department of Pharmacy, E-Da Hospital, Kaohsiung, China Taiwan
  • Abstract:

    Background

    Direct-acting antiviral agents, including ledipasvir (LDV)/sofosbuvir (SOF), are now novel therapeutic agents for chronic hepatitis C (CHC). However, the efficacy and safety of these agents is not fully explored in Taiwan.

    Methods

    Patients with CHC receiving LDV/SOF 90 mg/400 mg with or without ribavirin for 12 weeks in our hospital from

    ..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses